Stephens & Co. Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $420
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jacob Johnson maintains an Overweight rating on West Pharmaceutical Servs (NYSE:WST) and raises the price target from $400 to $420.
July 17, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
West Pharmaceutical Servs' price target has been raised from $400 to $420 by Stephens & Co. The firm maintains an Overweight rating on the stock.
The raised price target indicates that the analyst believes the stock has potential to perform well in the future. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100